Lantern Pharma Launches withZeta.ai, World's First Multi-Agentic AI Co-Scientist

New AI platform aims to accelerate rare cancer drug discovery and development

Apr. 14, 2026 at 5:44pm

Got story updates? Submit your updates here. ›

A highly detailed, glowing 3D illustration of a complex network of interconnected AI agents, data streams, and molecular structures in vibrant shades of neon cyan and magenta, conceptually representing the advanced AI technology behind Lantern Pharma's withZeta.ai platform.The advanced AI capabilities of withZeta.ai aim to revolutionize rare cancer drug discovery and development.San Diego Today

Lantern Pharma, a clinical-stage biopharmaceutical company, has announced the launch of withZeta.ai, the world's first multi-agentic artificial intelligence co-scientist designed to aid in the discovery and development of rare cancer drugs. The platform is now available with introductory, academic, and commercial subscription tiers, and will make its live debut at the Nasdaq MarketSite in New York City on April 16, 2026, followed by public demonstrations at the AACR 2026 conference in San Diego from April 17 to April 22.

Why it matters

The launch of withZeta.ai represents a significant advancement in the use of AI technology to accelerate the drug discovery and development process, particularly for rare and difficult-to-treat cancers. By leveraging a multi-agentic AI approach, Lantern Pharma aims to streamline the identification of promising drug candidates and optimize the clinical trial process, ultimately bringing new treatments to patients faster.

The details

withZeta.ai is a comprehensive AI platform that combines multiple specialized AI agents to assist researchers and drug developers in various aspects of the drug discovery and development pipeline. The platform utilizes advanced machine learning algorithms, natural language processing, and data analytics to analyze vast amounts of scientific literature, clinical trial data, and real-world evidence, helping to identify promising drug targets, predict drug efficacy and safety, and optimize the design of clinical trials.

  • Lantern Pharma will launch withZeta.ai with a live debut at the Nasdaq MarketSite in New York City on April 16, 2026 from 12:00 PM to 2:00 PM Eastern.
  • Public demonstrations of withZeta.ai will be held at the AACR 2026 conference in San Diego from April 17 to April 22, 2026.

The players

Lantern Pharma

A clinical-stage biopharmaceutical company that has developed withZeta.ai, the world's first multi-agentic AI co-scientist for rare cancer drug discovery and development.

withZeta.ai

Lantern Pharma's new AI platform that combines multiple specialized AI agents to assist researchers and drug developers in various aspects of the drug discovery and development pipeline.

Got photos? Submit your photos here. ›

What they’re saying

“We are thrilled to launch withZeta.ai, a groundbreaking AI platform that we believe will revolutionize the way rare cancer drugs are discovered and developed. By harnessing the power of multi-agentic AI, we aim to accelerate the identification of promising drug candidates and optimize the clinical trial process, ultimately bringing new treatments to patients faster.”

— Panna Sharma, CEO of Lantern Pharma

What’s next

Lantern Pharma will host live demonstrations of withZeta.ai at the Nasdaq MarketSite in New York City on April 16, 2026 and at the AACR 2026 conference in San Diego from April 17 to April 22, 2026, where the public can learn more about the platform and its capabilities.

The takeaway

The launch of withZeta.ai represents a significant step forward in the use of AI technology to streamline the drug discovery and development process, particularly for rare and difficult-to-treat cancers. By leveraging a multi-agentic approach, Lantern Pharma aims to accelerate the identification of promising drug candidates and optimize clinical trials, ultimately bringing new treatments to patients faster.